CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
The European Medicines Agency’s (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of Stallergenes…
Immunology
-
-
Advanz Pharma’s liver disease drug pulled from European market after court hearing
Advanz Pharma’s liver disease drug Ocaliva (obeticholic acid) will no longer be available in Europe after the General Court of…
-
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & Johnson's (J&J) nipocalimab…
-
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS Pharmaceuticals for…
-
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
Canadian biotech Aurinia Pharmaceuticals has announced it will be axing its workforce by 45% in a major restructuring plan aimed…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
Nektar Therapeutics to sell Alabama facility to Ampersand
US-based Nektar Therapeutics has signed a definitive agreement to divest its Huntsville, Alabama manufacturing facility and associated reagent supply business…
-
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr),…
-
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
As biosimilars continue to arrive on the psoriasis scene, wider measures to influence drug access and emerging treatment choices in…
-
GSK to acquire Chimagen’s CMG1A46 for autoimmune disease
GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for…
